Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
08 nov. 2018 07h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Licensed Jenrin Discovery’s extensive library of small molecules targeting the endocannabinoid system (ECS) positioning Corbus with the leading pipeline focused on treating inflammatory and fibrotic...
Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies
22 oct. 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Lenabasum is a first-in-class novel, synthetic oral cannabinoid designed to treat rare, serious autoimmune diseasesFavorable safety and tolerability profiles maintained with long-term chronic...
Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference
18 oct. 2018 16h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Study demonstrates that lenabasum decreases inflammatory biomarkers and increases pro-resolving mediators in airway macrophages from cystic fibrosis patientsCystic fibrosis is a life-threatening...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
26 sept. 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1st at 2:55 PM ET – – Leerink Partners Roundtable Series: Rare Disease & Oncology fireside chat...
Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union
18 sept. 2018 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as...
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
08 août 2018 09h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and JapanRecent long-term...
Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis
25 juil. 2018 09h20 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months12-month 150 subject study with ACR/EULAR 2016 Total...
Corbus Pharmaceuticals Receives FDA Orphan Drug Designation for Lenabasum for the Treatment of Dermatomyositis
20 juil. 2018 09h20 HE
|
Corbus Pharmaceuticals Holdings, Inc.
– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin – DM affects ~80,000 in the US, EU and Japan and has a 5-year mortality rate as high...
Corbus Pharmaceuticals Adds Two Key Executives to Lead its Regulatory and CMC Operations
22 mai 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
— Robert Discordia, Ph.D., named Vice President, Pharmaceutical Development & Manufacturing — — Ross Lobell named Vice President, Regulatory Affairs — Norwood, MA, May 22, 2018 (GLOBE...
Corbus Pharmaceuticals Announces Acceptance of Three Abstracts for Presentation at EULAR 2018 Annual Meeting
15 mai 2018 08h00 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Data from Phase 2 one-year open-label extension of lenabasum in systemic sclerosis and 6-month open-label extension data in dermatomyositis studies to be presented - Norwood, MA, May 15,...